IL324830A - Bicyclic peptide ligands specific for epha2 and their uses - Google Patents
Bicyclic peptide ligands specific for epha2 and their usesInfo
- Publication number
- IL324830A IL324830A IL324830A IL32483025A IL324830A IL 324830 A IL324830 A IL 324830A IL 324830 A IL324830 A IL 324830A IL 32483025 A IL32483025 A IL 32483025A IL 324830 A IL324830 A IL 324830A
- Authority
- IL
- Israel
- Prior art keywords
- dose
- patient
- cancer
- pharmaceutical composition
- administering
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2023/067777 WO2024248860A1 (fr) | 2023-06-01 | 2023-06-01 | Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées |
| US202363609655P | 2023-12-13 | 2023-12-13 | |
| PCT/GB2024/051423 WO2024246551A1 (fr) | 2023-06-01 | 2024-05-31 | Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL324830A true IL324830A (en) | 2026-01-01 |
Family
ID=91530249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL324830A IL324830A (en) | 2023-06-01 | 2024-05-31 | Bicyclic peptide ligands specific for epha2 and their uses |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4719480A1 (fr) |
| JP (1) | JP2026523407A (fr) |
| CN (1) | CN121889170A (fr) |
| AU (1) | AU2024279019A1 (fr) |
| IL (1) | IL324830A (fr) |
| WO (1) | WO2024246551A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119874840B (zh) * | 2025-03-31 | 2025-08-08 | 晶核生物医药科技(上海)有限公司 | 一种双环肽及其应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6074574B2 (ja) | 2008-02-05 | 2017-02-08 | バイシクル セラピューティクス リミテッド | 方法及び組成物 |
| CN114760988A (zh) * | 2019-11-27 | 2022-07-15 | 拜斯科技术开发有限公司 | 对EphA2具有特异性的双环肽配体和其用途 |
-
2024
- 2024-05-31 EP EP24732758.8A patent/EP4719480A1/fr active Pending
- 2024-05-31 AU AU2024279019A patent/AU2024279019A1/en active Pending
- 2024-05-31 JP JP2025569856A patent/JP2026523407A/ja active Pending
- 2024-05-31 CN CN202480048038.8A patent/CN121889170A/zh active Pending
- 2024-05-31 WO PCT/GB2024/051423 patent/WO2024246551A1/fr not_active Ceased
- 2024-05-31 IL IL324830A patent/IL324830A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN121889170A (zh) | 2026-04-17 |
| EP4719480A1 (fr) | 2026-04-08 |
| WO2024246551A1 (fr) | 2024-12-05 |
| AU2024279019A1 (en) | 2025-12-18 |
| JP2026523407A (ja) | 2026-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021234391A1 (fr) | Ligands peptidiques bicycliques spécifiques de la nectine 4 et leurs utilisations | |
| EP4065085A1 (fr) | Ligands de peptides bicycliques spécifiques de epha2 et utilisations associées | |
| JP2024543505A (ja) | 癌の治療方法 | |
| WO2017004092A1 (fr) | Association d'un inhibiteur de l'histone désacétylase (hdac) avec un anticorps anti-pdl-1 pour le traitement du cancer | |
| KR20250056270A (ko) | 활성화 fgfr3 유전자 변화를 갖는 고형 종양을 치료하는 방법 | |
| CA2694644A1 (fr) | Combinaisons pharmaceutiques | |
| AU2024279019A1 (en) | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR EphA2 AND USES THEREOF | |
| IL324868A (en) | Bicyclic peptide ligands specific for nectin-4 and uses thereof | |
| WO2024248859A1 (fr) | Ligands peptidiques bicycliques spécifiques de la nectine 4 et leurs utilisations | |
| WO2024248860A1 (fr) | Ligands de peptides bicycliques spécifiques d'epha2 et utilisations associées | |
| WO2023136837A1 (fr) | Utilisation de tivozanib et de durvalumab pour le traitement du carcinome hépatocellulaire (hcc) | |
| WO2025056907A1 (fr) | Ligands peptidiques bicycliques spécifiques de la nectine-4 et leurs utilisations | |
| WO2025125809A1 (fr) | Ligands peptidiques bicycliques spécifiques de la nectine-4 et leurs utilisations | |
| EA047123B1 (ru) | Бициклические пептидные лиганды, специфические для нектина-4, и их применение | |
| WO2025125648A1 (fr) | Complexe peptidique bicyclique destiné à être utilisé dans le traitement du cancer | |
| CN121843713A (zh) | 使用抗pd-1和化学疗法治疗肺癌 | |
| WO2025260061A1 (fr) | Compositions et méthodes de thérapie anticancéreuse | |
| WO2023230554A1 (fr) | Combinaison d'un inhibiteur de braf, d'un inhibiteur d'egfr et d'un antagoniste de pd-1 pour le traitement du cancer colorectal msi-h/dmmr, avec mutation v600e de braf |